Method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
First Claim
Patent Images
1. A method for revascularizing an ischemic region, comprising the steps of:
- (a) preparing a pharmaceutical composition comprising a recombinant fibroblast growth factor-1 (FGF-1); and
(b) injecting an amount of said pharmaceutical composition into the ischemic region, said amount being sufficient to induce local neoangiogenesis, wherein the FGF-1 is prepared by a process comprising the steps of;
(i) transforming an E. coli host cell with a plasmid comprising an expressible gene encoding a biologically active human acidic fibroblast growth factor protein, operably linked to a promoter;
(ii) infecting the transformed bacterial host cell with a bacteriophage λ
which mediates delayed lysis; and
(iii) cultivating the E. coli host cell under a culture condition that induces lytic growth of said cell without lysis until a desired level of production of said protein is reached, wherein said protein is produced as a soluble, biologically-active human acidic fibroblast growth factor protein.
8 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to the treatment of coronary heart disease by revascularization therapy, and more particularly to the intramyocardial injection of a pharmaceutical composition comprising a recombinant fibroblast growth factor-1 protein or a fragment of a recombinant fibroblast growth factor-1 protein, optionally, with a physiologic glue for inducing local neoangiogenesis in ischemic myocardium. Methods of producing the recombinant fibroblast growth factor 1 protein and fragments are also disclosed.
17 Citations
35 Claims
-
1. A method for revascularizing an ischemic region, comprising the steps of:
-
(a) preparing a pharmaceutical composition comprising a recombinant fibroblast growth factor-1 (FGF-1); and
(b) injecting an amount of said pharmaceutical composition into the ischemic region, said amount being sufficient to induce local neoangiogenesis, wherein the FGF-1 is prepared by a process comprising the steps of;
(i) transforming an E. coli host cell with a plasmid comprising an expressible gene encoding a biologically active human acidic fibroblast growth factor protein, operably linked to a promoter;
(ii) infecting the transformed bacterial host cell with a bacteriophage λ
which mediates delayed lysis; and
(iii) cultivating the E. coli host cell under a culture condition that induces lytic growth of said cell without lysis until a desired level of production of said protein is reached, wherein said protein is produced as a soluble, biologically-active human acidic fibroblast growth factor protein. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)
-
-
35. A method for treating coronary artery disease in a patient, comprising the steps of:
-
(a) preparing a pharmaceutical composition comprising a recombinant fibroblast growth factor-1 (FGF-1);
(b) injecting an amount of said pharmaceutical composition into at least one site in a heart wall, said amount being sufficient to improve myocardial perfusion; and
(c) injecting a composition comprising a physiological glue to a surface of the heart at the site(s) where the pharmaceutical composition was injected, wherein the FGF-1 is prepared by a process comprising the steps of;
(i) transforming an E. coli host cell with a plasmid comprising an expressible gene encoding a biologically active human acidic fibroblast growth factor protein, operably linked to a promoter;
(ii) infecting the transformed bacterial host cell with a bacteriophage λ
which mediates delayed lysis; and
(iii) cultivating the E. coli host cell under a culture condition that induces lytic growth of said cell without lysis until a desired level of production of said protein is reached, wherein said protein is produced as a soluble, biologically-active human acidic fibroblast growth factor protein.
-
Specification